NCT03035032 2024-11-26
A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients
Astellas Pharma Inc
Phase 4 Completed
Clinical Trials
5 trialsNCT05304169 2022-03-31
PRIZE
Zodiac Produtos Farmaceuticos S.A.
Phase 4 Completed
NCT01136226 2018-10-24
Eligard
Chesapeake Urology Research Associates
Phase 4 Completed
NCT01933022 2017-03-09
EFFECT
Astellas Pharma Inc
Phase 4 Terminated
NCT01511874 2015-09-23
Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
HanAll BioPharma Co., Ltd.
Phase 4 Completed